In 2015, Inovio Pharmaceuticals started a Phase I trial of INO-5150 — a new type of immunotherapy using a DNA vaccine for prostate cancer which targets both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA). At the recent ESMO meeting in Madrid, Spain, Shore et al. presented the results of this study. The following data […]![]()
